IL12B and pulmonary hypertension: Since severe LV failure often causes increased lung weight and WHO class II pulmonary hypertension, and since HF-induced lung remodeling also affects the clinical outcome in HF patients, we further determined the effect of anti-IL12β antibody on TAC-induced pulmonary function using SCIREQ’s flexiVent system.